The Pharma Data

JANUARY 17, 2021

18 , 2021 /PRNewswire/ — Hanmi Pharmaceutical Co., In particular, two new drugs developed by Hanmi Pharmaceutical Co., In particular, two new drugs developed by Hanmi Pharmaceutical Co., and “Oraxol,” which was licensed out to Athenex, Inc. Hanmi Pharmaceutical Co.,

FDA Approval 52

FDA Approval FDA Pharmaceuticals Clinical Trials 52

Drug Channels

OCTOBER 13, 2020

I am pleased to announce our new 2020–21 Economic Report on Pharmaceutical Wholesalers and Specialty Distributors , available for purchase and immediate download. Click here to download a free report overview (including the Table of Contents and a List of Exhibits) New Drug Channels Institute Study Examines Impact of COVID-19 on U.S.

Pharmaceuticals 52

Pharmaceuticals Licensing Licensing Pharmacy 52

The Pharma Data

NOVEMBER 15, 2020

” Arthur Oubrie, Chief Scientific Officer of Lead Pharma, added: “This is the second project we partner with one of the largest pharmaceutical companies under our Discover, Design and Deliver platform. View original content to download multimedia: [link]. . OSS, Netherlands , Nov. About Lead Pharma. Source link.

Small Molecule 52

Small Molecule Licensing Licensing Disease 52

Drug Channels

MARCH 15, 2022

Pharmacies and Pharmacy Benefit Managers , available for purchase and immediate download. Click here to download a free report overview (including key industry trends, the Table of Contents, and a List of Exhibits) New Drug Channels Institute Study Examines Consolidation and Vertical Integration of U.S. WHAT’S GOING ON.

Pharmacy 84

Pharmacy Specialty Pharmacies Licensing Licensing 84

The Pharma Data

NOVEMBER 25, 2020

25, 2020 /PRNewswire/ — Vivera Pharmaceuticals and Burkhan World today announce financial backing by JR Dallas Wealth Management in support of Vivera’s global growth strategies. “Our new partner, Vivera Pharmaceuticals, is the ideal strategic partner for our vision to make a difference in peoples’ lives.”

Pharmaceuticals 52

Pharmaceuticals Hospitals Pharmaceutical Companies Licensing 52

The Pharma Data

OCTOBER 19, 2020

20, 2020 /PRNewswire/ — CNS PHARMACEUTICALS AG , Inc. manufacturer, Pharmaceutics International, Inc. (“Pii”), has completed the manufacturing process for Berubicin Drug Product, its lead drug candidate for the treatment of glioblastoma multiforme (GBM), an aggressive form of brain cancer currently considered incurable.

Clinical Trials 52

Clinical Trials Trials Pharmaceuticals Treatment 52

The Pharma Data

OCTOBER 26, 2020

27, 2020 /PRNewswire/ — Aridis Pharmaceuticals, Inc. Dr. Hasan Jafri , Chief Medical Officer of Aridis Pharmaceuticals, will be a speaker on a panel entitled “Direct Antivirals and Other Agents Against SARS-CoV2 Virus.” About Aridis Pharmaceuticals, Inc. Aridis Pharmaceuticals, Inc. SAN JOSE, Calif. ,

Pharmaceuticals 52

Pharmaceuticals Virus Hospitals Clinical Trials 52

The Pharma Data

JANUARY 27, 2021

28, 2021 /PRNewswire/ — CASI Pharmaceuticals (Formerly Known As EntreMed, Inc.). technology platform simultaneously identifies both targets and the antibodies that bind to them, generating many promising new drug candidates to fuel the Company’s own clinical development pipeline or for additional licensing and partnering.

Pharmaceuticals 52

Pharmaceuticals Clinical Trials Licensing Licensing 52

The Pharma Data

DECEMBER 16, 2020

17, 2020 /PRNewswire/ — CNS Pharmaceuticals, Inc. We will now rapidly move to initiate our Phase 2 trial of Berubicin for adults with GBM and expect to begin enrolling patients in the first quarter of next year,” commented John Climaco , CEO of CNS Pharmaceuticals. About CNS Pharmaceuticals, Inc.

FDA Approval 52

FDA Approval FDA Pharmaceuticals Clinical Trials 52

The Pharma Data

JANUARY 13, 2021

“Receiving Fast Track designation is an important acknowledgment of the results of our COVID-19 laboratory research,” commented Leo Ehrlich, Chief Executive Officer at Innovation Pharmaceuticals. A preprint supporting Brilacidin’s COVID-19 treatment potential can be downloaded at the link below. Source link.

Clinical Trials 52

Clinical Trials Trials Treatment FDA 52

Drug Channels

OCTOBER 19, 2020

You can download the complete agenda here. Medical Plus – Tailored Track Options Based on Company Size : Emerging/Small Companies – Infrastructure Set-Up, License Procurement and 3PL Contracting Mid-Large Companies – How Do I Think About My Portfolio Differently Based on Product Type?

Specialty Pharmacies 52

Specialty Pharmacies Science Pharmacy Licensing 52

The Pharma Data

MAY 4, 2021

Lilly is offering donations of baricitinib to the Indian government through Direct Relief while simultaneously working with local Indian pharmaceutical companies to execute royalty-free voluntary licensing agreements to accelerate the manufacturing and distribution of the medicine in India during the pandemic. BA HCP ISI 09JUL2020.

Licensing 40

Licensing Licensing Therapies Laboratories 40

Metabolite Tales Blog

NOVEMBER 17, 2022

Teva Pharmaceuticals licensed laquinimod from Active Biotech. Download slides About Andrew Dr Andrew Parkinson is former Chief Executive Officer & Chief Scientific Officer of XenoTech, the contract research organization he founded in 1994 which has recently been acquired by BioIVT. This was unexpected.

International 52

International Licensing Licensing Treatment 52

The Pharma Data

DECEMBER 8, 2020

technology platform simultaneously identifies both targets and the antibodies that bind to them, generating many promising new drug candidates to fuel the company’s own clinical development pipeline or for additional licensing and partnering. The following files are available for download: View original content: [link].

Clinical Trials 40

Clinical Trials Licensing Licensing International 40

DrugBank

MARCH 22, 2024

Due to open source data’s accessibility, it is an appealing resource for drug research as it often enables cost-effective sources for emerging pharmaceutical companies and academic research projects.  Paid Knowledge Bases Paying for access or licensing a knowledge base can be a difficult decision to make.

Licensing 74

Licensing Licensing Research Production 74

The Pharma Data

JANUARY 19, 2021

BioInvent’s management team will also give an update on the ongoing Phase I/IIa trial of BI-1206 in combination with rituximab and BioInvent’s partner CASI Pharmaceuticals (NASDAQ: CASI) will provide an update on the development plan and potential for BI-1206 in China. The Company’s validated, proprietary F.I.R.S.T

Clinical Trials 40

Clinical Trials Licensing Licensing International 40

The Pharma Data

NOVEMBER 25, 2020

technology platform simultaneously identifies both targets and the antibodies that bind to them, generating many promising new drug candidates to fuel the Company’s own clinical development pipeline or for additional licensing and partnering. The following files are available for download: View original content: [link].

Clinical Trials 52

Clinical Trials Licensing Licensing International 52

The Pharma Data

DECEMBER 15, 2020

Under the agreement, Aurena Laboratories will establish a production unit to meet the regulatory requirements for the manufacture of Lipidor’s pharmaceutical products. This is an important step towards a licensing agreement for Lipidor drug candidates, AKP01 and AKP02, for the treatment of psoriasis. SOURCE Lipidor.

Production 52

Production Laboratories Licensing Licensing 52

The Pharma Data

JANUARY 26, 2021

The project portfolio is a combination of fully funded projects run in partnership with global pharmaceutical companies and innovative in-house projects with significant market and out-licensing potential. The following files are available for download: View original content: [link]. SOURCE BioArctic. Source link.

Disease 40

Disease Pharmaceutical Companies Treatment Licensing 40

The Pharma Data

NOVEMBER 26, 2020

27, 2020 /PRNewswire/ — BioInvent International AB ‘s (publ) (“BioInvent”) (OMXS: BINV) Extraordinary General Meeting (the “EGM”) today resolved to approve the Board of Directors’ resolution on a directed issue of 29,395,311 new shares and 14,697,655 new warrants to CASI Pharmaceuticals Inc.

Clinical Trials 52

Clinical Trials Licensing Licensing International 52

The Pharma Data

NOVEMBER 1, 2020

In addition, Corlieve has licensed REGENXBIO’s NAV AAV9 technology for the TLE program. who brings to the Company over 25 years of neuroscience leadership experience in the pharmaceutical and biotech industries, including most recently as Chief Operating Officer of Therachon Holding AG until its acquisition by Pfizer in July 2019.

Therapies 52

Therapies Science Treatment Disease 52

The Pharma Data

JANUARY 22, 2021

iosBio , a UK-based biotechnology company, has announced an exclusive worldwide licensing agreement with ImmunityBio , a clinical-stage immunotherapy company, for rights to use iosBio’s OraPro vaccine platform technology to test the oral administration of ImmunityBio’s vaccine candidate. Download this exclusive report here.

Vaccine 52

Vaccine Immune Response Government RNA 52

PPD

JULY 9, 2024

How the flex hub model saves one developer time and money As an example of the value that our flex hub model brings to biotech and pharmaceutical developers, here is a brief look at one long-term partnership in place since 2013. Ready to implement an FSP engagement as the ideal solution for all your lifecycle maintenance requirements?

Compliance 52

Compliance Production Clinical Research Marketing 52

Codon

FEBRUARY 13, 2024

Phage-based products have been licensed for use as antibacterial agents in the sanitation , food production , and animal health industries. Phages that can be essentially downloaded and synthesized by anyone, in any location, would solve those problems, he says. There is also a growing body of successful treatments in the U.S.,

Therapies 118

Therapies Virus DNA Clinical Trials 118

The Pharma Data

JANUARY 10, 2021

Sébastien Peltier, CEO of VALBIOTIS, and Jocelyn Pineau, CFO, are taking part in this key event for biotechnology and pharmaceutical companies. Download the slideshow of meetings on the Company website, in the Documentation section dedicated to investors: www.valbiotis.com/en/documents/.

International 40

International Pharmaceutical Companies Disease Licensing 40

The Pharma Data

JANUARY 13, 2021

. Psychedelic Pharmaceutical Scientist and Clinical Pharmacologist Robert Barrow Appointed as Chief Development Officer. View original content to download multimedia: [link]. NEW YORK , Jan. MindMed does not undertake any obligation to update publicly any forward-looking statement.

Clinical Trials 52

Clinical Trials FDA Trials Production 52

The Pharma Data

NOVEMBER 26, 2020

Food and Drug Administration (FDA) has extended the Prescription Drug User Fee Act (PDUFA) date for review of the Company’s Biologics License Application (BLA) seeking accelerated approval of pegunigalsidase alfa (PRX–102) for the proposed treatment of adult patients with Fabry disease. Protalix has licensed to Pfizer Inc.

Disease 52

Disease Treatment Clinical Trials FDA 52

The Pharma Data

NOVEMBER 10, 2020

AlzeCure ® is a Swedish pharmaceutical company that develops new innovative drug therapies for the treatment of severe diseases and conditions that affect the central nervous system, such as Alzheimer’s disease and pain – indications for which currently available treatment is extremely limited. STOCKHOLM , Nov.

Pharmaceutical Companies 40

Pharmaceutical Companies Disease Treatment Pharmaceuticals 40

The Pharma Data

NOVEMBER 2, 2020

2, 2020 /PRNewswire/ — BioMarin Pharmaceutical Inc. Europe, Latin America, the Middle East, and most of Asia Pacific, there are currently no licensed medicines for achondroplasia. This press release contains forward-looking statements about the business prospects of BioMarin Pharmaceutical Inc. 20, 2021. In the U.S.,

Drugs 40

Drugs FDA Treatment Pharmaceuticals 40

The Pharma Data

DECEMBER 20, 2020

technology platform simultaneously identifies both targets and the antibodies that bind to them, generating many promising new drug candidates to fuel the Company’s own clinical development pipeline or for additional licensing and partnering. The following files are available for download: View original content: [link].

Virus 52

Virus Trials Clinical Trials Clinical Development 52

Advarra

JULY 19, 2022

The sponsor is the pharmaceutical company conducting the trial. For more information on key components of a fit-for-purpose, phase-by-phase QMS guidance download Advarra’s whitepaper Steps to Implementing a Quality Management System. A: Working in a pharmaceutical company is the best way to learn this.

Packaging 52

Packaging FDA Trials Regulations 52

Molecule Blog

JANUARY 18, 2023

The current NFT owner can legally prove that they’re holding the IP rights by downloading and verifying the attached legal documents on their own machine. Those agreements denominate the owning entity of an intellectual property as the holder of an NFT on a certain collection.

Licensing 52

Licensing Licensing Packaging Laboratories 52

The Pharma Data

MAY 4, 2021

About OLUMIANT ® (baricitinib) OLUMIANT, a once-daily, oral JAK inhibitor was discovered by Incyte and licensed to Lilly. Lilly licensed etesevimab from Junshi Biosciences after it was jointly developed by Junshi Biosciences and the Institute of Microbiology , Chinese Academy of Science (IMCAS). It is approved in the U.S.

Therapies 52

Therapies Hospitals Treatment FDA Approval 52

The Pharma Data

OCTOBER 29, 2020

Baricitinib, an oral JAK1/JAK2 inhibitor discovered by Incyte, is developed by Lilly under license from Incyte. However, as with any pharmaceutical product, there are substantial risks and uncertainties in the process of development and commercialization. View original content to download multimedia: [link]. J Rheumatol.

Therapies 52

Therapies Treatment Disease Clinical Trials 52

The Pharma Data

OCTOBER 14, 2020

14, 2020 /PRNewswire/ — Harmony Biosciences Holdings, Inc. (“Harmony”) (Nasdaq: HRMY), a pharmaceutical company dedicated to developing and commercializing innovative therapies for patients living with rare neurological disorders who have unmet medical needs, today announced the U.S. PLYMOUTH MEETING, Pa. and CHICAGO , Oct.

FDA Approval 52

FDA Approval FDA Treatment Clinical Trials 52

The Pharma Data

MAY 15, 2021

Let me tell you my story… I lived a full, busy life working as a researcher in a pharmaceutical company, taught aerobics twice weekly in the evenings, volunteered at a local shelter during the weekend, and also did all the things that mothers do (2 children). other licensed healthcare provider. That’s all you have to do.

Doctors 52

Doctors Production Therapies Treatment 52

The Pharma Data

NOVEMBER 4, 2020

–( BUSINESS WIRE )– Concert Pharmaceuticals, Inc. President and Chief Executive Officer of Concert Pharmaceuticals. Please log on to the Concert website approximately 15 minutes prior to the scheduled webcast to ensure adequate time for any software downloads that may be required. 5, 2020 11:00 UTC. LEXINGTON, Mass.–(

Pharmaceuticals 52

Pharmaceuticals Clinical Trials Trials Treatment 52